187 related articles for article (PubMed ID: 36977915)
1. Systematic pan-cancer analysis identifies transmembrane protein 158 as a potential therapeutic, prognostic and immunological biomarker.
Li J; Hou H; Sun J; Ding Z; Xu Y; Li G
Funct Integr Genomics; 2023 Mar; 23(2):105. PubMed ID: 36977915
[TBL] [Abstract][Full Text] [Related]
2. HHLA2 Used as a Potential Prognostic and Immunological Biomarker and Correlated with Tumor Microenvironment in Pan-Cancer.
Yang Z; Xu D; Ye X; Lin X; Zhang M; Su Y; Xie Q; Ni W
Biomed Res Int; 2022; 2022():3924400. PubMed ID: 35252444
[TBL] [Abstract][Full Text] [Related]
3. Pan-cancer evidence of prognosis, immune infiltration, and immunotherapy efficacy for annexin family using multi-omics data.
Shen C; Zhang S; Zhang Z; Yang S; Zhang Y; Lin Y; Fu C; Li Z; Wu Z; Wang Z; Li Z; Guo J; Li P; Hu H
Funct Integr Genomics; 2023 Jun; 23(3):211. PubMed ID: 37358720
[TBL] [Abstract][Full Text] [Related]
4. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
Wang N; Zhu L; Wang L; Shen Z; Huang X
Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
[TBL] [Abstract][Full Text] [Related]
5. Pan-Cancer Analysis of the N6-Methyladenosine Eraser FTO as a Potential Prognostic and Immunological Biomarker.
Zhao C; Liu Y; Ju S; Wang X
Int J Gen Med; 2021; 14():7411-7422. PubMed ID: 34744452
[TBL] [Abstract][Full Text] [Related]
6. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
7. Pan-cancer analysis of the prognostic and immunological role of GJB2: a potential target for survival and immunotherapy.
Jia Y; Guo B; Zhang W; Wang F; Zhang Y; Zhang Q; Li E
Front Oncol; 2023; 13():1110207. PubMed ID: 37427102
[TBL] [Abstract][Full Text] [Related]
8. RecQ mediated genome instability 2 (
Wei W; Ying X; Chen L; Sun Q; Lu X; Xia Y; Xu R; Zhu Z; Zhang D; Tang Q; Li L; Xie J; Yu H
Aging (Albany NY); 2022 May; 14(9):4107-4136. PubMed ID: 35552266
[TBL] [Abstract][Full Text] [Related]
9. Pan-cancer analysis of N4-acetylcytidine adaptor THUMPD1 as a predictor for prognosis and immunotherapy.
Li K; Liu J; Yang X; Tu Z; Huang K; Zhu X
Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34762107
[TBL] [Abstract][Full Text] [Related]
10. A pan-cancer analysis to determine the prognostic analysis and immune infiltration of HSPA5.
Zhu RK; Zhang W; Zhang YX; Hui Z; Wang XW
Curr Cancer Drug Targets; 2023 May; ():. PubMed ID: 37157205
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive Analysis of
Liu J; Zhu B; Chen J; Cao Y
Anticancer Res; 2023 Oct; 43(10):4491-4509. PubMed ID: 37772558
[TBL] [Abstract][Full Text] [Related]
12. Clinical and immunological characteristics of TGM3 in pan-cancer: A potential prognostic biomarker.
Zhang W; Wu C; Zhou K; Cao Y; Zhou W; Zhang X; Deng D
Front Genet; 2022; 13():993438. PubMed ID: 36685895
[No Abstract] [Full Text] [Related]
13. POC1A, prognostic biomarker of immunosuppressive microenvironment in cancer.
Zhao Q; Gao S; Chen X; Zhu X
Aging (Albany NY); 2022 Jun; 14(12):5195-5210. PubMed ID: 35748773
[TBL] [Abstract][Full Text] [Related]
14. LncRNA WAC-AS1 expression in human tumors correlates with immune infiltration and affects prognosis.
Wang Y; Gong H; Cao Y
Hereditas; 2023 May; 160(1):26. PubMed ID: 37248547
[TBL] [Abstract][Full Text] [Related]
15. Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker.
Cheng X; Wang X; Nie K; Cheng L; Zhang Z; Hu Y; Peng W
Front Immunol; 2021; 12():646523. PubMed ID: 33679809
[TBL] [Abstract][Full Text] [Related]
16. A pan-cancer characterization of immune-related NFIL3 identifies potential predictive biomarker.
Fei Q; Zhang X; Wang S; Shu G; Yin G
J Cancer; 2024; 15(5):1271-1286. PubMed ID: 38356719
[No Abstract] [Full Text] [Related]
17. Pan-cancer analysis identifies RNF43 as a prognostic, therapeutic and immunological biomarker.
Xu Y; Lin Z; Ji Y; Zhang C; Tang X; Li C; Liu T
Eur J Med Res; 2023 Oct; 28(1):438. PubMed ID: 37848933
[TBL] [Abstract][Full Text] [Related]
18. A systematic analysis of
Jiang Y; Wang X; Li L; He J; Jin Q; Long D; Liu C; Zhou W; Liu K
Front Genet; 2022; 13():926943. PubMed ID: 35991552
[No Abstract] [Full Text] [Related]
19. Comprehensive Analysis of RELL2 as a Potential Biomarker Associated with Tumor Immune Infiltrating Cells in a Pan-Cancer Analysis.
Musha K; Ge X; Ablikim N; Lu B; Chen C; Huang J
Dis Markers; 2022; 2022():5009512. PubMed ID: 35634441
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive Pan-Cancer Analysis of GINS2 for Human Tumour Prognosis and as an Immunological Biomarker.
Meng W; Jiang Z; Zhang X; Cai B; Ma L; Guan Y
Comput Math Methods Med; 2022; 2022():3119721. PubMed ID: 36466552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]